Alvotech and Advanz Pharma Submit First Biosimilar Application for Eylea 8 mg
Event summary
- Alvotech and Advanz Pharma submitted a regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg, to the European Medicines Agency on October 14, 2026.
- The submission is the first known regulatory application worldwide for a biosimilar to Eylea 8 mg.
- AVT29 is a line extension to the existing marketing authorization for Mynzepli (aflibercept 2 mg), Alvotech’s biosimilar to Eylea 2 mg, which received European Commission approval in August 2025.
- Eylea 8 mg accounted for approximately 57% of combined global Eylea 2 mg and 8 mg sales by value in Q2 2026, up from 30% in the same period in 2025.
The big picture
This submission positions Alvotech and Advanz Pharma at the forefront of the next wave of aflibercept biosimilars, targeting a high-growth segment of the retinal disease market. The strategic partnership leverages Alvotech’s development capabilities and Advanz Pharma’s commercialization expertise to broaden access to affordable biologic medicines. The success of AVT29 could set a precedent for future biosimilar line extensions in the European market.
What we're watching
- Regulatory Approval
- Whether AVT29 will secure regulatory approval and the timeline for potential market entry.
- Market Penetration
- The pace at which Alvotech and Advanz Pharma can capture market share from Eylea 8 mg, given its significant revenue contribution.
- Competitive Dynamics
- How Regeneron and Bayer respond to the introduction of a biosimilar competitor in the retinal disease treatment space.
Related topics
